Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sinovet is a leading Chinese animal health biotechnology company founded in 2011 and headquartered in Taizhou, Jiangsu. The company specializes in the research, development, manufacturing, and commercialization of high-quality veterinary biological products, particularly vaccines and diagnostic reagents for swine, cattle, companion animals, and economic animals. Sinovet has established six advanced technology platforms, including suspension culture, genetic engineering, and heat-resistant protection, which have enabled the development of over 30 animal vaccines. Notable products include the world's first natural gene-deleted highly pathogenic porcine reproductive and respiratory syndrome (HP-PRRS) live vaccine (TJM-F92 strain) and various multi-valent combination vaccines.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sinovet.